MSB 3.19% 97.0¢ mesoblast limited

Cell Therapy News/Articles, page-17526

  1. 300 Posts.
    lightbulb Created with Sketch. 340
    Maybe this should be under a new thread but I will have to say that a cell product that deals with inflammatory conditions is pretty powerful, whether or not it is made in America:

    https://www.theage.com.au/national/the-silent-killer-why-medical-research-is-fired-up-about-inflammation-20211126-p59cdw.html

    The above was actually the best story of the (Sydney Morning Herald companion) Good Weekend magazine of 2022.

    The interesting thing is, most people are not aware that inflammation is just a topic that researchers are starting to know more of, as opposed to something that people already know a lot about. In this sense, it is pioneering science if you can come up with product platforms that address multiple inflammatory conditions in multiple organs. Despite what some of us will lament as a bad choice for a first indication, kids’ SR aGVHD approval will open many doors I believe.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
97.0¢
Change
0.030(3.19%)
Mkt cap ! $1.107B
Open High Low Value Volume
94.0¢ 98.0¢ 92.0¢ $3.342M 3.477M

Buyers (Bids)

No. Vol. Price($)
4 33313 97.0¢
 

Sellers (Offers)

Price($) Vol. No.
97.5¢ 73982 2
View Market Depth
Last trade - 16.10pm 03/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.